We are pleased to present Part 4 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.

Part 4 of this series provides peer-to-peer physician perspectives on the first results from the VIKTORIA-1 trial.

Topics include:

1. Mechanisms of resistance to CDK4/6 inhibitors
2. Rationale, design, and results of VIKTORIA-1 for the PIK3CA, wild-type cohort

Discussants:

Neil M. Iyengar, MD

Director, Survivorship Services, Winship Cancer Institute of Emory University

Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Atlanta, GA

Seth Wander, MD, PhD

Director, Precision Medicine, Termeer Center for Targeted Therapies

Director, Translational Research, Breast Oncology Program

Assistant Professor of Medicine, Harvard Medical School

Massachusetts General Hospital

Boston, MA

Sponsored by Lilly